Sofinnova Investments related stories
All articles and analysis
Fundraising recap: Summary of recent fund closings worldwideA summary of fund news from seed-stage focused Susa in the US to updates in Australia
Sofinnova collects $595.5 mln for tenth fundSofinnova Ventures has raised $595.5 million for its tenth fund, according to an SEC filing https://www.sec.gov/Archives/edgar/data/1680200/000168020016000001/xslFormDX01/primary_doc.xml The target is $650 million. The biopharmaceutical venture firm closed its ninth fund http://www.prnewswire.com/news-releases/sofinnova-raises-500-million-biotech-venture-fund-268246332.html at a hard cap of $500 million in July 2014.
- Just closed: Sofinnova Ventures raises $596m
View the latest closings
- VC-backed Audentes debuts IPO
San Francisco-based Audentes Therapeutics, a developer of gene therapy products for patients with serious, life-threatening rare diseases, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading July 20, 2016 on the NASDAQ under the ticker symbol "BOLD." BofA Merrill Lynch, Cowen and Company and Piper Jaffray are serving as the lead underwriters. Audentes' backers included Deerfield Management, Sofinnova Ventures, Venrock, OrbiMed, 5AM Ventures and Versant Ventures.
Worldwide fundraising briefsFrom Mucker in LA to Atomico in the UK, a recap of worldwide fundraising news
HealthQuest Capital closes second fund at $225 mln hard capHealthQuest Capital closed its second fund at its $225 million hard cap, exceeding an initial target of $175 million in commitments.
Investors are all ears when it comes to hearing ailmentsHearing-focused startups are bridging the gap of consumer electronics and healthcare, as hearing ailments become increasingly prevalent among younger people
Fund performance: San Francisco pension finds strong starts from IVP, Canaan, Weathergage fundsThe San Francisco Employees’ Retirement System is maintaining an aggressive approach to venture, and the reward has been several strong starts from among its recent bets